Page 1609 - Hematology_ Basic Principles and Practice ( PDFDrive )

1431.e4 Part VII Hematologic Malignancies

144. Thalhammer-Scherrer R, Geissler K, Schwarzinger I, et al: Fludarabine 165. Treon SP, Branagan AR, Ioakimidis L, et al: Long term outcomes to
therapy in Waldenström’s macroglobulinemia. Ann Hematol 79:556, fludarabine and rituximab in Waldenström’s macroglobulinemia. Blood
2000. 113:3673, 2009.
145. Dhodapkar MV, Jacobson JL, Gertz MA, et al: Prognostic factors 166. Tam CS, Wolf MM, Westerman D, et al: Fludarabine combination
and response to fludarabine therapy in patients with Waldenström therapy is highly effective in first-line and salvage treatment of patients
macroglobulinemia: results of United States intergroup trial (Southwest with Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma
Oncology Group S9003). Blood 98:41, 2001. 6:136, 2005.
146. Zinzani PL, Gherlinzoni F, Bendandi M, et al: Fludarabine treatment 167. Hensel M, Villalobos M, Kornacker M, et al: Pentostatin/
in resistant Waldenström’s macroglobulinemia. Eur J Haematol 54:120, cyclophosphamide with or without rituximab: an effective regimen for
1995. patients with Waldenström’s macroglobulinemia/lymphoplasmacytic
147. Leblond V, Ben Othman T, Deconinck E, et al: Activity of fludarabine lymphoma. Clin Lymphoma Myeloma 6:131, 2005.
in previously treated Waldenström’s macroglobulinemia: a report of 71 168. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al: Primary
cases. J Clin Oncol 16:2060, 1998. treatment of Waldenström’s macroglobulinemia with dexamethasone,
148. Dimopoulos MA, Weber DM, Kantarjian H, et al: 2-Chlorodeoxy- rituximab and cyclophosphamide. J Clin Oncol 25:3344, 2007.
adenosine therapy of patients with Waldenström macroglobulinemia 169. Buske C, Hoster E, Dreyling MH, et al: The addition of rituximab
previously treated with fludarabine. Ann Oncol 5:288, 1994. to front-line therapy with CHOP (R-CHOP) results in a higher
149. Lewandowski K, Halaburda K, Hellmann A: Fludarabine therapy in response rate and longer time to treatment failure in patients with
Waldenström’s macroglobulinemia patients treated previously with lymphoplasmacytic lymphoma: results of a randomized trial of the
2-chlorodeoxyadenosine. Leuk Lymphoma 43:361, 2002. German Low-Grade Lymphoma Study Group (GLSG). Leukemia 23:
150. Popat U, Saliba R, Thandi R, et al: Impairment of filgrastim-induced 153, 2009.
stem cell mobilization after prior lenalidomidein patients with multiple 170. Treon SP, Hunter Z, Branagan A: CHOP plus rituximab therapy in
myeloma. Biol Blood Marrow Transplant 15:718, 2009. Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 5:273,
151. Leleu XP, Manning R, Soumerai JD, et al: Increased incidence of 2005.
transformation and myelodysplasia/acute leukemia in patients with 171. Ioakimidis L, Patterson CJ, Hunter ZR, et al: Comparative outcomes
Waldenström macroglobulinemia treated with nucleoside analogs. J following CP-R, CVP-R and CHOP-R in Waldenström’s macroglobu-
Clin Oncol 27:250, 2009. linemia. Clin Lymphoma Myeloma 9:62, 2009.
152. Leleu X, Tamburini J, Roccaro A, et al: Balancing risk versus benefit 172. Rummel M, Niederle N, Maschmeyer G, et al: Bendamustine plus
in the treatment of Waldenström’s macroglobulinemia patients with rituximab versus CHOP plus rituximab as first-line treatment for
nucleoside analogue based therapy. Clin Lymphoma Myeloma 9:71, patients with indolent and mantle-cell lymphomas: an open-label, mul-
2009. ticentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203,
153. Treon SP, Kelliher A, Keele B, et al: Expression of serotherapy target 2013.
antigens in Waldenström’s macroglobulinemia: Therapeutic applica- 173. Treon SP, Hanzis C, Tripsas C, et al: Bendamustine therapy in patients
tions and considerations. Semin Oncol 30:248, 2003. with relapsed or refractory Waldenström’s macroglobulinemia. Clin
154. Treon SP, Agus DB, Link B, et al: CD20-directed antibody-mediated Lymphoma Myeloma Leuk 211:133, 2011.
immunotherapy induces responses and facilitates hematologic recovery 174. Dimopoulos MA, Hamilos G, Efstathiou E, et al: Treatment of
in patients with Waldenström’s macroglobulinemia. J Immunother Waldenström’s macroglobulinemia with the combination of fludarabine
24:272, 2001. and cyclophosphamide. Leuk Lymphoma 44:993, 2003.
155. Gertz MA, Rue M, Blood E, et al: Multicenter phase 2 trial of ritux- 175. Tamburini J, Levy V, Chateilex C, et al: Fludarabine plus cyclophos-
imab for Waldenström macroglobulinemia (WM): an Eastern Coop- phamide in Waldenström’s macroglobulinemia: results in 49 patients.
erative Oncology Group study (E3A98). Leuk Lymphoma 45:2047, Leukemia 19:1831, 2005.
2004. 176. Treon SP, Ioakimidis L, Soumerai JD, et al: Primary therapy of
156. Dimopoulos MA, Zervas C, Zomas A, et al: Treatment of Waldenström’s Waldenström’s macroglobulinemia with bortezomib, dexamethasone
macroglobulinemia with rituximab. J Clin Oncol 20:2327, 2002. and rituximab. J Clin Oncol 27:3830, 2009.
157. Treon SP, Emmanouilides C, Kimby E, et al: Extended rituximab 177. Ghobrial IM, Matous J, Padmanabhan S, et al: Phase II trial of com-
therapy in Waldenström’s macroglobulinemia. Ann Oncol 16:132, bination of bortezomib and rituximab in relapsed and/or refractory
2005. Waldenström’s macroglobulinemia. Blood 112:832, 2008.
158. Treon SP, Branagan AR, Hunter Z, et al: Paradoxical increases in 178. Agathocleous A, Rohatiner A, Rule S, et al: Weekly versus twice weekly
serum IgM and viscosity levels following rituximab in Waldenström’s bortezomib given in conjunction with rituximab in patients with recur-
macroglobulinemia. Ann Oncol 15:1481, 2004. rent follicular lymphoma, mantle cell lymphoma, and Waldenström
159. Ghobrial IM, Fonseca R, Greipp PR, et al: Initial immunoglobulin M macroglobulinemia. Br J Haematol 151:346, 2010.
“flare” after rituximab therapy in patients with Waldenström macro- 179. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al: Primary
globulinemia: an Eastern Cooperative Oncology Group study. Cancer therapy of Waldenström macroglobulinemia (WM) with weekly bort-
101:2593, 2004. ezomib, low-dose dexamethasone, and rituximab (BDR): long-term
160. Dimopoulos MA, Anagnostopoulos A, Zervas C, et al: Predictive results of a phase 2 study of the European Myeloma Network (EMN).
factors for response to rituximab in Waldenström’s macroglobulinemia. Blood 122:3276, 2013.
Clin Lymphoma 5:270, 2005. 180. Treon SP, Palomba ML, Tripsas CK, et al: Ibrutinib in previously treated
161. Treon SP, Hansen M, Branagan AR, et al: Polymorphisms in FcγRIIIA patients with Waldenström’s macroglobulinemia. Paper presented at the
(CD16) receptor expression are associated with clinical responses to 8th International Workshop on Waldenström’s Macroglobulinemia,
rituximab in Waldenström’s macroglobulinemia. J Clin Oncol 23:474, London, UK, August 14–16, 2014. Abstract 91.
2005. 181. Ghobrial IM, Witzig TE, Gertz M, et al: Long-term results of the phase
162. Dimopoulos MA, Anagnostopulos A, Kyrtsonis MC, et al: Treatment II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed
of relapsed or refractory Waldenström’s macroglobulinemia with bort- or refractory Waldenström macroglobulinemia. Am J Hematol 89:237,
ezomib. Haematologica 90:1655, 2005. 2014.
163. Chen CI, Kouroukis CT, White D, et al: Bortezomib is active in 182. Treon SP, Tripsas CK, Meid K, et al: Prospective, multicenter study
patients with untreated or relapsed Waldenström’s macroglobulinemia: of the mTOR inhibitor everolimus (RAD001) as primary therapy in
a phase II study of the National Cancer Institute of Canada Clinical Waldenström’s macroglobulinemia. Blood 122:1822, 2013.
Trials Group. J Clin Oncol 25:1570, 2007. 183. Treon SP, Hanzis C, Manning RJ, et al: Maintenance rituximab is
164. Weber DM, Dimopoulos MA, Delasalle K, et al: 2-Chlorodeoxyadenosine associated with improved clinical outcome in rituximab naïve patients
alone and in combination for previously untreated Waldenström’s with Waldenström’s macroglobulinemia who respond to a rituximab
macroglobulinemia. Semin Oncol 30:243, 2003. containing regimen. Br J Haematol 154:357, 2011.